Tag: Daratumumab

Throughout the chronicles of hematologic oncology, from the empirical observations of plasma cell dyscrasias documented in nineteenth-century medical literature to the molecular sophistication of contemporary immunotherapy, the therapeutic paradigm has remained fundamentally reactive—intervening only upon manifestation of overt malignancy. Where once clinicians maintained vigilant surveillance of precancerous states through expectant observation, the field now confronts…